Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 31

1.

The co-occurrence of epilepsy and autism: A systematic review.

Lukmanji S, Manji SA, Kadhim S, Sauro KM, Wirrell EC, Kwon CS, Jetté N.

Epilepsy Behav. 2019 Sep;98(Pt A):238-248. doi: 10.1016/j.yebeh.2019.07.037. Epub 2019 Aug 6. Review.

PMID:
31398688
2.

N/OFQ-NOP System in Peripheral and Central Immunomodulation.

Kadhim S, Bird MF, Lambert DG.

Handb Exp Pharmacol. 2019;254:297-311. doi: 10.1007/164_2018_203.

PMID:
30771012
3.

Resveratrol-Mediated Attenuation of Staphylococcus aureus Enterotoxin B-Induced Acute Liver Injury Is Associated With Regulation of microRNA and Induction of Myeloid-Derived Suppressor Cells.

Kadhim S, Singh NP, Zumbrun EE, Cui T, Chatterjee S, Hofseth L, Abood A, Nagarkatti P, Nagarkatti M.

Front Microbiol. 2018 Dec 17;9:2910. doi: 10.3389/fmicb.2018.02910. eCollection 2018.

4.

Opioids, gliosis and central immunomodulation.

Kadhim S, McDonald J, Lambert DG.

J Anesth. 2018 Oct;32(5):756-767. doi: 10.1007/s00540-018-2534-4. Epub 2018 Jul 27. Review.

PMID:
30054718
5.

Osseointegration evaluation of laser-deposited titanium dioxide nanoparticles on commercially pure titanium dental implants.

Azzawi ZGM, Hamad TI, Kadhim SA, Naji GA.

J Mater Sci Mater Med. 2018 Jun 26;29(7):96. doi: 10.1007/s10856-018-6097-6.

PMID:
29946975
6.

Validating screening tools for depression in Parkinson's disease.

Kadhim S, Pringsheim T, Le A, Fiest KM, Patten SB, Prisnie JC, Gill S, Bulloch AGM, Hu B, Jette N.

Mov Disord. 2018 Jul;33(7):1184-1186. doi: 10.1002/mds.27371. Epub 2018 Mar 24. No abstract available.

PMID:
29573354
7.

Preclinical Profile of AB-423, an Inhibitor of Hepatitis B Virus Pregenomic RNA Encapsidation.

Mani N, Cole AG, Phelps JR, Ardzinski A, Cobarrubias KD, Cuconati A, Dorsey BD, Evangelista E, Fan K, Guo F, Guo H, Guo JT, Harasym TO, Kadhim S, Kultgen SG, Lee ACH, Li AHL, Long Q, Majeski SA, Mao R, McClintock KD, Reid SP, Rijnbrand R, Snead NM, Micolochick Steuer HM, Stever K, Tang S, Wang X, Zhao Q, Sofia MJ.

Antimicrob Agents Chemother. 2018 May 25;62(6). pii: e00082-18. doi: 10.1128/AAC.00082-18. Print 2018 Jun.

8.

Treatment of pain in SAPHO (synovitis, acne, pustulosis, hyperostosis, and osteitis) syndrome.

Kim CH, Kadhim S, Julien C.

PM R. 2014 Jan;6(1):92-5. doi: 10.1016/j.pmrj.2013.08.610.

PMID:
24439152
9.

Discovery of 7-aminofuro[2,3-c]pyridine inhibitors of TAK1: optimization of kinase selectivity and pharmacokinetics.

Hornberger KR, Chen X, Crew AP, Kleinberg A, Ma L, Mulvihill MJ, Wang J, Wilde VL, Albertella M, Bittner M, Cooke A, Kadhim S, Kahler J, Maresca P, May E, Meyn P, Romashko D, Tokar B, Turton R.

Bioorg Med Chem Lett. 2013 Aug 15;23(16):4511-6. doi: 10.1016/j.bmcl.2013.06.054. Epub 2013 Jun 27.

PMID:
23856049
10.

Enzymatic depletion of tumor hyaluronan induces antitumor responses in preclinical animal models.

Thompson CB, Shepard HM, O'Connor PM, Kadhim S, Jiang P, Osgood RJ, Bookbinder LH, Li X, Sugarman BJ, Connor RJ, Nadjsombati S, Frost GI.

Mol Cancer Ther. 2010 Nov;9(11):3052-64. doi: 10.1158/1535-7163.MCT-10-0470. Epub 2010 Oct 26.

11.
12.

Antitumor activity of troxacitabine (Troxatyl) against anthracycline-resistant human xenografts.

Gourdeau H, Genne P, Kadhim S, Bibeau L, Duchamp O, Ouellet F, deMuys JM, Bouffard DY, Attardo G.

Cancer Chemother Pharmacol. 2002 Dec;50(6):490-6. Epub 2002 Oct 16.

PMID:
12451476
13.

Synergistic anti-tumor activity of a novel immunomodulator, BCH-1393, in combination with cyclophosphamide.

Kadhim S, Penney C, Lagraoui M, Heibein J, Attardo G, Zacharie B, Connolly T, Gagnon L.

Int J Immunopharmacol. 2000 Sep;22(9):659-71.

PMID:
10884587
14.

Inhibition of tumor growth with doxorubicin in a new orthotopically implanted human hepatocellular carcinoma model.

Labonté P, Kadhim S, Bowlin T, Mounir S.

Hepatol Res. 2000 Jul;18(1):72-85.

PMID:
10838038
15.

Prevention of bladder tumor formation in mice by a novel bone marrow-derived factor, reptimed.

Khandaker MH, Kadhim SA, Ichim TE, Howson-Jan K, Chin J, Singhal SK.

Anticancer Res. 2000 Jan-Feb;20(1A):183-9.

PMID:
10769653
16.

Synthesis and activity of dipeptides, linked to targeting ligands, as specific NK cell enhancers.

Abbott SD, Gagnon L, Lagraoui M, Kadhim S, Attardo G, Zacharie B, Penney CL.

J Med Chem. 1998 May 21;41(11):1909-26.

PMID:
9599240
17.

Potent antitumor activity of a novel nucleoside analogue, BCH-4556 (beta-L-dioxolane-cytidine), in human renal cell carcinoma xenograft tumor models.

Kadhim SA, Bowlin TL, Waud WR, Angers EG, Bibeau L, DeMuys JM, Bednarski K, Cimpoia A, Attardo G.

Cancer Res. 1997 Nov 1;57(21):4803-10.

18.

Genetically regulated response to intravesical bacillus Calmette Guerin immunotherapy of orthotopic murine bladder tumor.

Kadhim SA, Chin JL, Batislam E, Karlik SJ, Garcia B, Skamene E.

J Urol. 1997 Aug;158(2):646-52.

PMID:
9224385
19.

Mycobacterium cell wall: an alternative to intravesical bacillus Calmette Guerin (BCG) therapy in orthotopic murine bladder cancer.

Chin JL, Kadhim SA, Batislam E, Karlik SJ, Garcia BM, Nickel JC, Morales A.

J Urol. 1996 Sep;156(3):1189-93.

PMID:
8709344
20.

Metallothionein expression and resistance to cisplatin in a human germ cell tumor cell line.

Koropatnick J, Kloth DM, Kadhim S, Chin JL, Cherian MG.

J Pharmacol Exp Ther. 1995 Dec;275(3):1681-7.

PMID:
8531144
21.

Metallothionein in testicular germ cell tumors and drug resistance. Clinical correlation.

Chin JL, Banerjee D, Kadhim SA, Kontozoglou TE, Chauvin PJ, Cherian MG.

Cancer. 1993 Nov 15;72(10):3029-35.

PMID:
8221570
22.

Modulation of both cisplatin nephrotoxicity and drug resistance in murine bladder tumor by controlling metallothionein synthesis.

Satoh M, Kloth DM, Kadhim SA, Chin JL, Naganuma A, Imura N, Cherian MG.

Cancer Res. 1993 Apr 15;53(8):1829-32.

23.

Magnetic resonance imaging for detecting and treatment monitoring of orthotopic murine bladder tumor implants.

Chin J, Kadhim S, Garcia B, Kim YS, Karlik S.

J Urol. 1991 Jun;145(6):1297-301.

PMID:
2033720
24.

Characterization of MBT-2 tumour cell "variant" resistant to tumour necrosis factor.

Kadhim SA, Wang JY, McLean B, Chin JL.

Urol Res. 1991;19(1):63-8.

PMID:
2028563
27.

In vivo induction of tumor variants by phorbol 12-myristate 13-acetate.

Kadhim S, Burns BF, Birnboim HC.

Cancer Lett. 1987 Dec;38(1-2):209-14.

PMID:
3690509
28.
29.

The roles of two peritoneal T-lymphocyte populations in the in vivo rejection of methylcolanthrene-induced sarcoma.

Kadhim SA, Rees RC, Barrington-Leigh J.

Cell Immunol. 1985 Jan;90(1):234-41.

PMID:
2578328
30.

Enhancement of tumor growth in mice: evidence for the involvement of host macrophages.

Kadhim SA, Rees RC.

Cell Immunol. 1984 Aug;87(1):259-69.

PMID:
6611212
31.

Studies on the high- and low-affinity rosette-forming T-lymphocytes in patients with Hodgkin's and non-Hodgkin's lymphoma.

Kadhim S, Rees RC, Potter CW, Walker R, Hancock BW.

Eur J Cancer. 1981 May;17(5):569-75. No abstract available.

PMID:
6975211

Supplemental Content

Loading ...
Support Center